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In a recent issue of Critical Care, Maria Schroeder et al.
[1] reported a prospective observational study involving
85 patients who had positive Aspergillus cultures or had
only a positive galactomannan test. They hypothesized
that a diagnostic algorithm including the detection of
galactomannan in bronchoalveolar lavage fluid (BALF)
would increase the diagnostic sensitivity for invasive pul-
monary aspergillosis (IPA) in intensive care unit (ICU)
patients. The result of this study indicated that the
diagnostic sensitivity for IPA could be increased by apply-
ing a cutoff value of 0.5 in BALF galactomannan as an
additional entry criterion for the AspICU clinical algo-
rithm. Based on the knowledge of the previous research,
we would like to make some remarks.
BALF galactomannan assay is recommended as an
accurate marker for the diagnosis of IPA in adult and
pediatric patients or even in patients receiving mold-
active antifungal therapy or prophylaxis [2]. However,
there is no consensus on its cutoff index and values of
0.5,1.0 and 3.0 have been reported in clinical studies. One
systematic review and meta-analysis including 30 diagnos-
tic studies evaluated the BALF galactomannan assay for
diagnosing IPA and revealed that the assay had higher
sensitivity with an optimal cutoff index of 1.0 compared
with a cutoff index of 0.5. The sensitivity was even higher
than the polymerase chain reaction (PCR) and serum
galactomannan test [3]. No standardized procedure for
extracting BALF has been published yet and different
studies have taken different approaches to collecting
BALF. As the yield of BALF is low, different methods af-
fected the BALF assay and led to different results.
The sensitivity of galactomannan in serum varies from
29 to 100 %, especially in severely immunocompromised
patients who were admitted to ICU because of infectious
diseases which led to the AspICU protocol not including
Aspergillus antigen testing [4]. It is a possible concern
that factors associated with false negative results for the
galactomannan assay in serum, such as prophylactic use
of antifungal drugs and immunocompromised patients,
can also result in false negative results when measuring
galactomannan in BALF [4]. More importantly, it is diffi-
cult to identify patients who are in the early stage of
IPA, particularly when the serum galactomannan test
does not yield clear results and the BALF galactomannan
test shows a positive result [5].
In conclusion, although the galactomannan assay in
BALF is the current trend for diagnosing IPA, the cutoff
index and BALF procedures need to be standardized,
taking into account factors that may affect the results.
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